Effect of 500 μg roflumilast on exercise tolerance and respiratory reserve in patients with chronic obstructive pulmonary disease. A 12 weeks double blind study with roflumilast once daily versus placebo. The INSPIRE Study

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].

A phase 3, multi-center, double-blind, randomized, placebo-controlled, single-blind baseline period study in subjects with chronic obstructive pulmonary disease (COPD).